Market Insights 

The chronic kidney disease market share was valued at USD 65.88 billion in 2022. The chronic kidney disease market industry is projected to grow from USD 69.44 Billion in 2023 to USD 100.34 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.40% during the forecast period (2023 - 2030). Rising occurrences of chronic diseases and the severity of kidney disease has increased the demand for an effective treatment option for the disease. Causes of chronic diseases are often indicated by diabetes, polycystic kidney disease, and high blood pressure among others. 

Increasing R&D activities with regards to diagnostics and treatment are expected to offer market growth opportunities in the future. Moreover, developing economies offer a wider scope for growth during the forecast period and are expected to affect the market positively.

Increasing prevalence of kidney diseases and the increased number of biopsy procedures have resulted in high demand for new diagnostic and treatment options for such chronic diseases. The global chronic kidney disease market has become highly competitive with the increasing entry of new market players; this is expected to stimulate growth during the forecast period. Kidney disease symptoms are often negligible in the initial phases, and this type of disease is widely referred to as a "silent disease" as detection often happens when the diseases are progressed to a later stage. This has increased the need for appropriate diagnostic measures and is driving market growth. 

Market Segmentation

MRFR's report segments the global chronic kidney disease market on the basis of diagnosis, treatment, indication, and end-user. By diagnosis, the market is segmented into blood test, urine test, imaging test, and kidney biopsy. By treatment, the market is segmented into drugs, dialysis, and kidney transplant. Drugs are further sub-segmented to include ace inhibitors, angiotensin-ii receptor blockers, calcium channel blockers, beta-blockers, and erythropoiesis-stimulating agents.

By indication, the chronic kidney disease market outlook is segmented into Type 1 or Type 2 diabetes, high blood pressure, polycystic kidney disease, and others. By end-user, The market is segmented into hospitals and clinics, diagnostic centers, and others. Globally, the market is divided into the Americas, Europe, Asia-Pacific & the Middle East and Africa.

Regional Analysis

The Americas and Europe are significant regional markets which have a similar growth pattern. The growth of medical devices, increasing awareness regarding kidney diseases and the rapid increase in occurrences of chronic diseases is expected to drive growth in these regions. Moreover, they display a robust demand for new treatment methods and options. Opportunities for these markets are being driven by the increasing emphasis on the development of new drugs. Supportive government legislature with regards to research & development and the availability of funds for research in these regions is expected to push the market in a forward direction.

Asia-Pacific is another important market due to its rapid growth. Prevalence of diseases such as diabetes and cardiovascular diseases are driving the demand for appropriate treatment options. The region has a rapidly improving healthcare sector which has improved infrastructure, and a wide pool of skilled healthcare professionals. Demand for advanced treatment technologies and other healthcare technology is expected to provide the market with opportunities for market expansion.

Key Players

MRFRs report includes the analysis of market players participating in the global chronic kidney diseases competitive landscape. Top market players include Hoffman-La Roche Ltd., Abbott, AstraZeneca Plc, Pfizer, Nova Biomedical, ARKRAY, OPTI Medical, and AbbVie to name a few.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.